NCT07219485
A Study of Pitolisant in Participants With Prader-Willi Syndrome
Enrolling by Invitation
PHASE3Ages 7+InterventionalTreatmentHarmony Biosciences Management, Inc.
~150 participants
Updated 2026-03-17 on ClinicalTrials.gov
What's tested:Pitolisant
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants reporting Treatment-Emergent Adverse Events (TEAEs)
Measured over From the end of the EOT visit of the parent study through 30 days after the final dose of study drug.
Conditions
NCT07219485
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Science 37
Morrisville, North Carolinano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David Seiden, MD · STUDY_DIRECTOR · Harmony Biosciences Management, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of participants reporting Treatment-Emergent Adverse Events (TEAEs)From the end of the EOT visit of the parent study through 30 days after the final dose of study drug.
A treatment-emergent adverse event (TEAE) is any adverse event reported during treatment with study drug in this study and up to 30 days after final dose of study drug, or any worsening of a pre-existing condition reported during treatment with study drug and up to 30 days after final dose of study drug.